-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QnWB5nw5PFZBO7czUPoNWlYbILuwD7QvV4UjCe34dt0EjegN9/9BuDRrS8YKegQU /i0EU7LYx88e0E96Vcxe2A== 0001030653-09-000023.txt : 20091005 0001030653-09-000023.hdr.sgml : 20091005 20091005163108 ACCESSION NUMBER: 0001030653-09-000023 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20091001 FILED AS OF DATE: 20091005 DATE AS OF CHANGE: 20091005 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SHANNON TIMOTHY M CENTRAL INDEX KEY: 0001207114 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23223 FILM NUMBER: 091105903 MAIL ADDRESS: STREET 1: C/O CURAGEN CORP STREET 2: 555LONG WHARF DR. 11TH FL. CITY: NEW HAVEN STATE: CT ZIP: 06511 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CURAGEN CORP CENTRAL INDEX KEY: 0001030653 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 061331400 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 322 EAST MAIN STREET CITY: BRANFORD STATE: CT ZIP: 06405 BUSINESS PHONE: 203 481 1104 MAIL ADDRESS: STREET 1: 322 EAST MAIN STREET CITY: BRANFORD STATE: CT ZIP: 06405 4 1 edgar.xml PRIMARY DOCUMENT X0303 4 2009-10-01 1 0001030653 CURAGEN CORP CRGN 0001207114 SHANNON TIMOTHY M 322 EAST MAIN STREET BRANFORD CT 06405 1 1 0 0 Former President and CEO Common Stock 2009-10-01 4 D 0 241740 D 0 D Stock Option (Right to Buy) .68 2009-10-01 4 D 0 569500 D 2010-10-01 Common Stock 569500 0 D Stock Option (Right to Buy) 1.34 2009-10-01 4 D 0 500000 D 2010-10-01 Common Stock 500000 0 D Disposed of pursuant to merger agreement between issuer and Celldex Therapeuitcs, Inc. in exchange for 66,212 shares of Celldex Therapeutics, Inc. common stock having a market value of $19.82 per share on the effective date of the merger, October 1, 2009. This option, which accelerated on October 1, 2009, was assumed by Celldex Therapeutics, Inc. in the merger and replaced with an option to purchase 155,986 shares of Celldex Therapeutics, Inc. common stock for $2.48 per share. This option, which vested 25% on September 25, 2008 and 6.25% quarterly thereafter, was assumed by Celldex Therapeutics, Inc. in the merger and replaced with an option to purchase 136,950 shares of Celldex Therapeutics, Inc. common stock for $4.89 per share. Timothy M. Shannon 2009-10-05 -----END PRIVACY-ENHANCED MESSAGE-----